Hola,
Are you new here?

I have an account

Conecta con

+150K Projects

+300K Companies

+230 Financiaciones

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

PregInPoxVac

financed

Closed

MATERNAL AND INFANT SAFETY AND IMMUNOGENICITY IN A PHASE 3 OPEN LABEL RANDOMIS...

MATERNAL AND INFANT SAFETY AND IMMUNOGENICITY IN A PHASE 3 OPEN LABEL RANDOMISED VACCINE TRIAL OF A TWO DOSE MPOX VACCINE Mpox can cause severe complications in vulnerable groups such as pregnant women and children, necessitating targeted public health interventions and vaccine trials in these populations. Limited data suggest the MVA-BN vaccine is s... see more

31/07/2027

unknown leader

2M€

Project Budget: 2M€

Project leader unknown leader

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 4 Participantes

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2024-08-26

HORIZON-JU-GH-EDCTP3-2024-Mpox: Mobilisation of Emergency funding f... Expected Outcome:This topic aims at supporting activities that contribute to answering the most pres...

I+D

Cerrada does 1 year

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

FONDAZIONE PENTA ETS

AFRICA CLINICAL RESEARCH MAN...

UNIVERSITEIT ANTWERPEN

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 35 months Date Start: 2024-08-26
End date: 2027-07-31

Project leader unknown leader

Project Budget 2M€

participation deadline Sin fecha límite de participación.

Project description Mpox can cause severe complications in vulnerable groups such as pregnant women and children, necessitating targeted public health interventions and vaccine trials in these populations. Limited data suggest the MVA-BN vaccine is safe for pregnant women and likely poses no risk to breastfed infants, but comprehensive human data are lacking. Trials in endemic areas are crucial for evaluating the vaccine's safety and efficacy in real-world settings. Vaccine hesitancy, exacerbated by misinformation and distrust in healthcare systems, poses a significant challenge, especially in the Democratic Republic of the Congo. Pregnant women are particularly affected by concerns about vaccine safety, which influences their willingness to vaccinate. Addressing these concerns through targeted communication and community engagement is vital. A proposed phase 3, randomized trial will assess the safety and immunogenicity of the MVA-BN vaccine in healthy pregnant and postpartum women and in infants/children (6-24 months old). Additionally, a qualitative study on vaccine hesitancy will inform the trial design and implementation, aiming to enhance vaccination uptake in these high-risk groups.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers

What is innovating.Works? Lose yourself in the best search engine for innovative companies you've ever seen, see how your competition is funded, connect with that partner you didn't know about, discover R&D projects that need you, and much, much more just a click away.

Smart Company-Financial Motor Innovating tiene un perfil tecnológico financiero de 400.000 empresas gracias al cual sabe a qué ayuda puede ir o no cualquier empresa de forma automática. Parece magia pero es tecnología.

Create your project and find partners ¿Tienes un proyecto y buscas un partner? Una Universidad, Centro Tecnológico, Consultoría? Este es tu sitio. Gracias al motor de búsqueda podemos recomendarte los mejores socios y ponerte en contacto con ellos.